Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pappas Capital is a global venture capital and commercial development firm founded in 1994 and based in Durham, North Carolina. Over the past 31 years, the firm has established itself as a key player in the life sciences sector, focusing on next-generation companies that aim to improve patient outcomes. Pappas Capital operates three primary lines of business: Pappas Ventures, which is its flagship life science venture arm; Specialized Fund Management, which creates and manages custom investment vehicles; and Translational Medicine, which partners with research universities to accelerate the development of scientific discoveries.
Currently, Pappas Capital manages a diverse portfolio of over 100 companies, emphasizing sectors such as healthcare, biotechnology, and agriculture. The firm has built strong relationships with academic institutions, enhancing its ability to translate scientific research into viable products. With a commitment to delivering substantial returns to investors, Pappas Capital continues to evolve and adapt to the changing landscape of life sciences and technology.
Pappas Capital invests primarily in the life sciences sector, including biotechnology, biopharmaceuticals, drug delivery, and medical devices. The firm targets opportunities across various stages, from seed stage to later-stage mezzanine transactions, with a particular interest in companies at Phase 1 or Phase 2 of development. Pappas Capital emphasizes strong proprietary positions, well-defined markets, and effective management teams when evaluating potential investments.
The firm operates three distinct lines of business: Pappas Ventures focuses on funding innovative life science companies; Specialized Fund Management structures customized investment vehicles tailored to specific needs; and Translational Medicine collaborates with academic institutions to accelerate scientific advancements. This multifaceted approach allows Pappas Capital to maintain a strong presence in the healthcare and biotech sectors while maximizing the potential for successful outcomes.
Pappas Capital has invested in over 100 companies, showcasing a diverse portfolio in the life sciences and biotechnology sectors. Notable portfolio companies include:
This extensive portfolio reflects Pappas Capital's commitment to advancing healthcare through innovative solutions and technologies.
Art Pappas: Founder and Managing Partner, with extensive experience in venture capital and a focus on life sciences.
Nikki Heron: Chief Financial Officer, responsible for financial strategy and operations.
Drew Cutshaw, MD: Principal and Medical Officer, brings medical expertise to the investment process.
Phillip Graham: Principal, involved in sourcing and evaluating investment opportunities.
Tom Mathers: Partner, focuses on strategic partnerships and portfolio management.
Richard Pascoe: Senior Advisor, providing insights and guidance based on his industry experience.
Charles Gersbach, PhD: Member of the Scientific Advisory Board, contributing scientific expertise.
Rodolphe Barrangou, PhD: Member of the Scientific Advisory Board, known for his work in biotechnology.
Pappas Capital operates several initiatives to support innovation in the life sciences sector. One notable program is the Wake Forest Technology Development Program, a partnership with Wake Forest University. This program aims to accelerate the development of innovative life science technologies, with a commitment of $15 million to support 25 to 30 technologies over four to five years.
This initiative exemplifies Pappas Capital's dedication to fostering scientific advancements and translating research into viable products, further enhancing its role as a key player in the life sciences investment space.
Recently, Pappas Capital has been active in the market, highlighting significant developments within its portfolio. Notable events include Aktis Oncology's initial public offering, which marks a significant milestone for the company and the firm. Additionally, Cadrenal Therapeutics has acquired a new therapeutic asset, showcasing ongoing engagement with their portfolio companies.
These developments indicate Pappas Capital's commitment to supporting its investments and staying connected with the broader life sciences community. The firm regularly publishes updates and insights on its website, reflecting its active role in the industry.
What are Pappas Capital's investment criteria?
Pappas Capital focuses on innovative life science, agriculture, and technology companies. They seek opportunities across various stages, particularly in companies at Phase 1 or Phase 2 of development. The firm emphasizes strong proprietary positions, well-defined markets, and effective management teams.
How can I pitch to Pappas Capital?
Founders can reach out through the firm's website or contact them directly via phone. A well-prepared pitch deck should include details about the technology, market opportunity, and team. Pappas Capital values clear communication and a strong understanding of the competitive landscape.
What makes Pappas Capital different from other investors?
Pappas Capital's unique approach includes three lines of business: Pappas Ventures, Specialized Fund Management, and Translational Medicine. This structure allows them to tailor investments and partnerships effectively, particularly with academic institutions, to accelerate scientific advancements.
What is the geographic focus of Pappas Capital?
The firm invests primarily in the United States, Canada, and Asia, targeting innovative companies in these regions.
What is the typical check size for investments?
Pappas Capital invests across various stages, with check sizes varying based on the specific needs of the company and the stage of development. They are known to participate in seed stage to later-stage mezzanine transactions.
What kind of support do portfolio companies receive?
Pappas Capital provides operational support, mentorship, and access to their extensive network within the life sciences community. They actively engage with portfolio companies to help them achieve their goals and enhance their market position.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.